Alvotech (NASDAQ:ALVO) Shares Gap Down – Time to Sell?

Alvotech (NASDAQ:ALVO) gapped down before the market opened on Thursday. The stock had previously closed at $4.92, but opened at $4.50. Alvotech shares last traded at $4.6130, with a volume of 313,273 shares trading hands.

Alvotech News Roundup

Investors following ALVO have been watching these news items:

• Negative Sentiment: Third-quarter revenue was $111.6 million, below the $125.2 million analyst estimate. Nine-month adjusted revenue fell 23% year over year to $323.4 million, while gross margin declined to 54% from 59%. Alvotech Q3 results
• Negative Sentiment: Management maintained 2026 revenue guidance of $650 million to $700 million but now expects performance toward the low end, adding caution about the pace of recovery and planned fourth-quarter deliveries. Alvotech results and business update
• Negative Sentiment: Cash fell to $61.5 million from $172.4 million at year-end 2025, and operating cash flow was negative $205.6 million over the first nine months—raising liquidity concerns amid substantial debt and financing needs. Alvotech results and business update

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the company. Evercore initiated coverage on Alvotech in a report on Friday, August 14th. They issued an “outperform” rating on the stock. Jefferies Financial Group began coverage on Alvotech in a research note on Tuesday. They set a “buy” rating and a $9.00 price objective for the company. Wall Street Zen downgraded Alvotech from a “hold” rating to a “sell” rating in a research report on Saturday, November 7th. Weiss Ratings upgraded Alvotech from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, November 4th. Finally, Barclays upgraded shares of Alvotech from an “underweight” rating to an “overweight” rating and boosted their target price for the stock from $4.00 to $8.00 in a report on Wednesday, September 16th. Five equities research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, Alvotech presently has a consensus rating of “Hold” and an average target price of $8.40.

Alvotech Stock Performance

The company’s fifty day moving average is $5.27 and its two-hundred day moving average is $4.21. The company has a market cap of $1.42 billion, a price-to-earnings ratio of -7.76 and a beta of 0.24.

Alvotech (NASDAQ:ALVO) last issued its quarterly earnings data on Wednesday, November 11th. The company reported ($0.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.04) by $0.01. The company had revenue of $111.60 million during the quarter, compared to analyst estimates of $125.20 million. On average, sell-side analysts anticipate that Alvotech will post -0.01 EPS for the current fiscal year.

Institutional Investors Weigh In On Alvotech

Large investors have recently made changes to their positions in the stock. ProShare Advisors LLC acquired a new stake in shares of Alvotech during the 3rd quarter worth approximately $68,000. Commonwealth Equity Services LLC acquired a new position in Alvotech in the third quarter valued at approximately $69,000. Mirae Asset Global Investments Co. Ltd. purchased a new position in Alvotech in the third quarter worth approximately $100,000. China Universal Asset Management Co. Ltd. grew its position in Alvotech by 24.3% in the third quarter. China Universal Asset Management Co. Ltd. now owns 61,712 shares of the company’s stock worth $365,000 after acquiring an additional 12,049 shares during the period. Finally, Renaissance Technologies LLC increased its stake in Alvotech by 146.9% during the first quarter. Renaissance Technologies LLC now owns 63,200 shares of the company’s stock worth $217,000 after acquiring an additional 37,600 shares during the last quarter.

Alvotech Company Profile

Alvotech is a biopharmaceutical company based in Reykjavik, Iceland, focused on developing and manufacturing biosimilars—medicines designed to be highly similar to existing biologic drugs. Its work includes biosimilars for conditions in areas such as immunology and oncology. Founded in 2013 by entrepreneur Robert Wessman, the company operates an integrated development and manufacturing platform in Iceland. Alvotech works with commercial partners to seek regulatory approval for and distribute its products in markets including the United States and Europe.